Delcath Systems Inc (DCTH)

$9.99 -0.24 (-2.35%)
Market Cap 357.86M
Revenue (ttm) 37.21M
Net Income (ttm) -26.39M
EPS (ttm) N/A
PE Ratio 86.50
Forward PE 79.85
Profit Margin -70.92%
Debt to Equity Ratio 0.00
Volume 1,695,496
Avg Vol 741,322
Day's Range N/A - N/A
Shares Out 34.98M
Stochastic %K 7%
Beta 0.84
Analysts Strong Sell
Price Target $23.80

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices
Sector: Healthcare
Phone: 212 489 2100
Fax: 212 489 2102
Address:
566 Queensbury Avenue, New York, United States
brunoq14
brunoq14 Oct. 27 at 8:31 PM
$DCTH Looking forward to what Michel has to say, pretty much about everything. Only about a week to go until earnings.
1 · Reply
actuallysam
actuallysam Oct. 27 at 7:21 PM
$DCTH Momentum also enforces fear in this case. The underlying issues are we never have the vision of insiders and it is always just an educated guess with this product as to how much market penetration. On the downside, we all would prefer to be treated with short infusions such as Kimmtrak that in spite of the frequent and sometimes severe side effects, treatment discontinuation due to adverse events was relatively low at 3.3% in clinical trials. Kimmtrak probably will make you tired etc. with first treatment usually the harshest.
0 · Reply
1ightningscalps
1ightningscalps Oct. 27 at 6:44 PM
1ightning® Options Trade Alert (Actionable) | Buy $DCTH Nov 21 $12 Call | Enter: $0.45 Exit: $0.79 | Profit: 76.43% ROI | https://1ightning.com
0 · Reply
actuallysam
actuallysam Oct. 27 at 4:51 PM
$DCTH The price suggests that maybe $150 million revenue will be the ceiling for the next 3 years, so anything better than that would be gravy.
1 · Reply
Playthegame06
Playthegame06 Oct. 27 at 4:30 PM
$DCTH ALGORITHMS are killing DCTH
0 · Reply
Bed_
Bed_ Oct. 27 at 4:25 PM
If $DCTH drops to 9.00–8.80, that’ll be a historical buying zone.
0 · Reply
Bed_
Bed_ Oct. 27 at 4:21 PM
$DCTH is extremely undervalued
0 · Reply
HypnoTrader
HypnoTrader Oct. 27 at 2:59 PM
$DCTH test of $9.8 first.
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Oct. 27 at 2:47 PM
$DCTH .. so let's find the bottom for reversal. Yawn.
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Oct. 27 at 2:46 PM
$SRPT I expect a similar ER like $DCTH (note, they were earnings positive, slightly). Meaning a step back from sequential .. but otherwise nicely looking fwd.
0 · Reply
Latest News on DCTH
Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 21, 2025, 8:30 AM EDT - 6 days ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Oct 20, 2025, 5:05 PM EDT - 7 days ago

Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript

Delcath: Large Upside With Limited Downside Risk

Oct 20, 2025, 3:06 PM EDT - 7 days ago

Delcath: Large Upside With Limited Downside Risk

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:15 PM EDT - 9 days ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Oct 18, 2025, 4:13 PM EDT - 9 days ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 22, 2025, 4:01 PM EDT - 5 weeks ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 4:01 PM EDT - 7 weeks ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate in Upcoming Investor Conferences

Aug 21, 2025, 8:30 AM EDT - 2 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 19, 2025, 8:30 AM EDT - 2 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:06 PM EDT - 2 months ago

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Aug 6, 2025, 8:00 AM EDT - 2 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:01 PM EDT - 3 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jul 23, 2025, 4:01 PM EDT - 3 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Delcath Systems: Growing Fast, But Business Model Is Fragile

Jun 12, 2025, 8:36 AM EDT - 4 months ago

Delcath Systems: Growing Fast, But Business Model Is Fragile

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025, 7:00 AM EDT - 5 months ago

Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 18, 2025, 8:25 AM EDT - 5 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 15, 2025, 4:30 PM EDT - 5 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 5:30 PM EDT - 6 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:55 AM EDT - 6 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

May 8, 2025, 7:30 AM EDT - 6 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 6 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 24, 2025, 4:01 PM EDT - 6 months ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 9, 2025, 5:00 PM EDT - 7 months ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Apr 2, 2025, 11:49 AM EDT - 7 months ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 24, 2025, 4:01 PM EDT - 7 months ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 14, 2025, 4:01 PM EDT - 8 months ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 2:17 PM EST - 8 months ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Mar 6, 2025, 8:00 AM EST - 8 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 20, 2025, 8:30 AM EST - 8 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Feb 14, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 9 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 9 months ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 8:00 AM EST - 10 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 4:01 PM EST - 10 months ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 30, 2024, 8:00 AM EST - 10 months ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Dec 2, 2024, 8:30 AM EST - 11 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Begins Platform Expansion With Two Phase 2 Trials

Nov 20, 2024, 7:50 AM EST - 1 year ago

Delcath Begins Platform Expansion With Two Phase 2 Trials

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Nov 18, 2024, 7:09 AM EST - 1 year ago

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 12:30 PM EST - 1 year ago

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

Aug 23, 2024, 3:30 PM EDT - 1 year ago

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

TEM

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

Aug 18, 2024, 10:03 PM EDT - 1 year ago

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

brunoq14
brunoq14 Oct. 27 at 8:31 PM
$DCTH Looking forward to what Michel has to say, pretty much about everything. Only about a week to go until earnings.
1 · Reply
actuallysam
actuallysam Oct. 27 at 7:21 PM
$DCTH Momentum also enforces fear in this case. The underlying issues are we never have the vision of insiders and it is always just an educated guess with this product as to how much market penetration. On the downside, we all would prefer to be treated with short infusions such as Kimmtrak that in spite of the frequent and sometimes severe side effects, treatment discontinuation due to adverse events was relatively low at 3.3% in clinical trials. Kimmtrak probably will make you tired etc. with first treatment usually the harshest.
0 · Reply
1ightningscalps
1ightningscalps Oct. 27 at 6:44 PM
1ightning® Options Trade Alert (Actionable) | Buy $DCTH Nov 21 $12 Call | Enter: $0.45 Exit: $0.79 | Profit: 76.43% ROI | https://1ightning.com
0 · Reply
actuallysam
actuallysam Oct. 27 at 4:51 PM
$DCTH The price suggests that maybe $150 million revenue will be the ceiling for the next 3 years, so anything better than that would be gravy.
1 · Reply
Playthegame06
Playthegame06 Oct. 27 at 4:30 PM
$DCTH ALGORITHMS are killing DCTH
0 · Reply
Bed_
Bed_ Oct. 27 at 4:25 PM
If $DCTH drops to 9.00–8.80, that’ll be a historical buying zone.
0 · Reply
Bed_
Bed_ Oct. 27 at 4:21 PM
$DCTH is extremely undervalued
0 · Reply
HypnoTrader
HypnoTrader Oct. 27 at 2:59 PM
$DCTH test of $9.8 first.
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Oct. 27 at 2:47 PM
$DCTH .. so let's find the bottom for reversal. Yawn.
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Oct. 27 at 2:46 PM
$SRPT I expect a similar ER like $DCTH (note, they were earnings positive, slightly). Meaning a step back from sequential .. but otherwise nicely looking fwd.
0 · Reply
xcdvfxcvnbxxvsd
xcdvfxcvnbxxvsd Oct. 27 at 2:45 PM
$DCTH short interest ath https://finviz.com/quote.ashx?t=DCTH&p=d&ty=si
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 27 at 9:29 AM
Enter: $DCTH Calls Strike Price: $12 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.45 Sell Price: $0.66 Profit : +46% (Turn every $1 into $1.46) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 26 at 8:20 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $DCTH Current Share Price: $10.23 Contracts: $DCTH May 15, 2026 $12 Calls Scale in: $1.83- $2.24 Scale out: $2.85-$3.67 Can Easily Capture: 60% ROI Blended DTE: 201 Days | Join Elites here: https://liquidtheta.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 26 at 1:45 PM
Enter: $DCTH Calls Strike Price: $12 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.45 Sell Price: $0.66 Profit : +46% (Turn every $1 into $1.46) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 10:42 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $DCTH Current Share Price: $10.23 Contracts: $DCTH May 15, 2026 $12 Calls Scale in: $1.83- $2.24 Scale out: $2.85-$3.67 Can Easily Capture: 60% ROI Blended DTE: 202 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Greenpa
Greenpa Oct. 25 at 7:31 PM
$DCTH To the point made earlier. I should known this!!!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 6:53 PM
Enter: $DCTH Calls Strike Price: $12 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.45 Sell Price: $0.66 Profit : +46% (Turn every $1 into $1.46) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Greenpa
Greenpa Oct. 25 at 2:51 PM
$DCTH My suppositions seems justified. Excerpt from Gemini: pharmaceutical companies frequently fund studies, partner, or acquire companies involved in developing devices or advanced drug delivery mechanisms to enhance the outcomes of their drugs. This is a significant trend because better drug delivery can improve efficacy, reduce side effects, increase patient compliance (especially for chronic conditions), and potentially extend the life cycle of a successful drug. The global market for advanced drug delivery systems is substantial and a key area of focus for the pharmaceutical industry, including in oncology
0 · Reply
actuallysam
actuallysam Oct. 25 at 2:48 PM
$DCTH Unless there is something severely hidden, I think analysts are low balling their revenue estimates for 2026.
1 · Reply
Greenpa
Greenpa Oct. 25 at 2:42 PM
$DCTH Wonder if some pharma companies will want studies of the synergy associated with Hepzato and their respective therapies? And then would they fund — as I think happens in other contexts (eg, Amgen with VSTM).
0 · Reply
agamemnus
agamemnus Oct. 24 at 8:45 PM
$DCTH HypnoTrader is an idiot with no capacity for self censorship
2 · Reply
mar99
mar99 Oct. 24 at 8:11 PM
$DCTH Quite a lousy week. Very very disappointing way to go into the weekend. Maybe somehow Gerard will find something uplifting to say in 1 1/2 weeks on the call. Just something to get us out of the dumps.
1 · Reply